Physician profile
Daniel M Geller
NPI 1861460743
$4,326.70
in general payments reported to CMS, 2019-2025
22 companies · $929 in 2025
The $929 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $163 · 2021: $385 · 2022: $748 · 2023: $738 · 2024: $869 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,536.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,136.82 | 2019-2025 | Cequa |
| Abbvie INC. | $562.56 | 2022-2025 | |
| Alcon Vision LLC | $363.10 | 2019-2025 | Eysuvis, Tryptyr, Clareon |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $360.49 | 2019-2021 | |
| Oyster Point Pharma, INC. | $353.08 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $341.98 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $261.29 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Kala Pharmaceuticals, INC. | $153.69 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $151.03 | 2019-2023 | |
| Dompe US, INC. | $146.41 | 2019-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $74.95 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $72.65 | 2020-2021 | |
| Astellas Pharma US INC | $67.36 | 2024-2025 | Izervay |
| Thea Pharma INC. | $63.00 | 2023-2024 | Iyuzeh |
| Allergan, INC. | $60.49 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $29.83 | 2024 | Eylea Hd |
| Apellis Pharmaceuticals, INC. | $29.77 | 2023 | Syfovre |
| Amgen INC. | $24.93 | 2025 | Tepezza |
| Biotissue Holdings INC. | $22.20 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $19.61 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $17.51 | 2019 | |
| Oasis Medical, INC. | $13.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Geller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.